22370-18-9 Usage
Uses
Used in Pharmaceutical Industry:
4-(Aminomethyl)-1(2H)-phthalazinone is used as a synthetic intermediate for the development of pharmaceutical compounds due to its ability to facilitate the creation of diverse bioactive molecules. Its presence in the synthesis process aids in the discovery and production of new therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(Aminomethyl)-1(2H)-phthalazinone is utilized as a key component in the synthesis of agrochemicals, contributing to the development of effective products for agricultural applications. Its reactivity and structural properties make it suitable for creating compounds that address various agricultural needs.
Used in Drug Discovery:
4-(Aminomethyl)-1(2H)-phthalazinone is employed as a precursor in drug discovery, where its unique structural features enable the design and synthesis of novel bioactive compounds with potential therapeutic applications. Its role in this process is crucial for advancing the development of new pharmaceutical products.
Overall, 4-(Aminomethyl)-1(2H)-phthalazinone's multifaceted applications across different industries highlight its importance in the creation of innovative solutions in healthcare and agriculture.
Check Digit Verification of cas no
The CAS Registry Mumber 22370-18-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,2,3,7 and 0 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 22370-18:
(7*2)+(6*2)+(5*3)+(4*7)+(3*0)+(2*1)+(1*8)=79
79 % 10 = 9
So 22370-18-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H9N3O/c10-5-8-6-3-1-2-4-7(6)9(13)12-11-8/h1-4H,5,10H2,(H,12,13)
22370-18-9Relevant academic research and scientific papers
TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN
-
Page/Page column 94-95, (2010/02/11)
The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders - such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to α2δ-1 subunit of Ca channels.
